ClinicalTrials.gg
RecruitingNCT06191263RIVER-81Updated Sep 18, 2026

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

A Phase 2 interventional study of RVU120 and Venetoclax in Acute Myeloid Leukemia, sponsored by Ryvu Therapeutics SA. Recruiting at 37 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Ryvu Therapeutics SA · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Leukemia, Myeloid, Acute with a site in Poland — 14 open to participants now, 23 under way, 11 of them phase 3. Leukemia, Myeloid, Acute · Poland.

Planned enrollment
54th of 75
98 · median 255
Started
2024
with 4 others
Phase 2
17 of 76
4 open now
Primary completion
2027-08
later than 9 of 22 live
Registered
67th of 76
by date
Lead sponsor
4 of 76
Ryvu Therapeutics SA

Among the 76 studies in Leukemia, Myeloid, Acute with a site in Poland, this one is the 54th largest by planned enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2024, is one of 17 in phase 2, reaches primary completion later than 9 of the 22 other live ones, and was the 67th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

14 of the 76 studies in Leukemia, Myeloid, Acute with a site in Poland are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Leukemia, Myeloid, Acute with a site in Poland, or all of them as a file.
02

Study summary

The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia (AML) who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent. The study consists of three parts. Part 1 aims to identify the doses of RVU120 and venetoclax that are considered to be safe and tolerated. Part 2 will assess the safety and efficacy of the doses selected. And Part 3 is a confirmatory cohort where patients will be treated at the same doses assessed in Part 2

Read the detailed description

In Part 1 dose-escalation participants will receive escalating oral doses of RVU120 starting at 125 mg administered every other day on days 1-13, and escalating oral doses of venetoclax starting with 200 mg administered daily on days 1-14 of each 21-day cycle of treatment. The recommended doses for further study will be based on the observed safety, tolerance, PK and PD.

In Part 2, it will be assessed whether the recommended dose level from Part 1 reaches the targetted response criteria, and if reached, Part 3 will be initiated to further evaluate the efficacy and safety of the recommended doses in a larger population.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a diagnosis of AML (per 2022 WHO classification)
  • Patients must have AML (per ELN 2022 criteria)
  • Patients must have failed treatment with venetoclax combined with a hypomethylating agent
  • Patients must have no alternative therapeutic options likely to produce clinical benefit
  • Patients must have performance status of 0 to 2
  • Patients must have adequate end organ function defined as:

    1. WBC \< 25 x 10(9)/L on Day 1 prior to first dose of study drug
    2. count > 10,000/mcL on Day 1 prior to first dose of study drug
    3. (aspartate transaminase) and ALT (alanine transaminase) ≤ 3 x (upper limit of normal)
    4. Total ≤ 3 x ULN
    5. (Cockcroft \& Gault formula) ≥ 50 mL/min
    6. (left ventricular ejection fraction) ≥ 40% by electrocardiography
  • Subjects must have the ability to understand and the willingness to sign a written document and complete study related procedures

Exclusion criteria

Exclusion Criteria:

  • APL (acute promyelocytic leukemia), the M3 subtype of AML
  • Active CNS (central nervous system) leukemia
  • Previous treatment with CDK8 and/or CDK19-targeted therapy
  • Major surgery within 28 days prior to the first dose of study drug
  • Hematopoietic stem cell transplant within 120 days prior to the first dose of study drug
  • Currently pregnant or breast-feeding. Females of child bearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study drug
  • Uncontrolled intercurrent illness that could limit or ability to complete study correlates. This includes but is not limited to:

    1. Active, Grade ≥2 acute (graft versus host disease) or requirement for systemic medication for GVHD
    2. Evidence of ongoing or uncontrolled systemic bacterial, fungal or viral infection and acute inflammatory conditions (including pancreatitis)
    3. Ongoing significant liver disease such as cirrhosis, drug-induced liver injury, active hepatitis, or chronic persistent and/or
    4. Ongoing drug-induced pneumonitis
    5. Significant cardiac dysfunction, defined as myocardial infarction within 12 months prior to the first dose of study drug, (New York Heart Association) Class III or IV heart failure, uncontrolled dysrhythmias, poorly controlled angina
    6. History of ventricular arrhythmia or ≥ 470 ms (Bazett's formula)
    7. Prior history of other than AML, unless disease-free for 5 years or more or prior basal cell carcinoma of the skin, non- squamous cell carcinoma of the skin, carcinoma in situ of cervix, breast or bladder, and incidental histological finding of prostate cancer (TMN stage T1a or T1b)
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RVU120 and/or venetoclax
  • Taking any medications, herbal supplements, or other substances (including smoking( that are known to be strong inhibitors or moderate/strong inducers or sensitive substrates of CYP1A2
  • Taking any medications, over-the-counter medications, foods or herbal supplements that are known to be strong or moderate inhibitors of or P-gp (P-glycoprotein)
  • Known allergy or to any component of RVU120 or venetoclax formulations
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    RVU120 + Venetoclax

    RVU120 oral capsule, 125 or 250 mg administered every other day on Days 1-13 of each 21-day cycle of treatment, combined with venetoclax oral tablet, 200 or 400 mg administered once daily on Days 1-14 of each 21-day cycle of treatment

    Drug: RVU120 · Drug: Venetoclax

Interventions

  • DrugRVU120

    Drug pages: SEL-120 · Romaciclib · Silevertinib

    RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

    Also known as: SEL120

  • Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis

06

What researchers measure

Primary outcomes

  1. (Part 1) recommended doses of RVU120 and venetoclax for further study

    Incidence and severity of toxicities and number of dose limiting toxicities per dose cohort

    Time frame: approx. 12 months

  2. (Parts 2 & 3) CR/CRh rate (Complete Remission/Complete Remission with incomplete Hematologic Recovery)

    Preliminary efficacy of RVU120 combined with venetoclax to recommended doses from Part 1. A response of CRh is defined as bone marrow with \<5% blasts, peripheral blood neutrophil count \>0.5 x 10(3)/mcL, and peripheral blood platelet count of \>0.5 x 10(5)/mcL

    Time frame: approx. 36 months

Secondary outcomes

  1. Incidence and severity of adverse events (safety and tolerability)

    Number and grade of adverse events assessed by CTCAE v5.0

    Time frame: approx. 36 months

  2. Duration of response

    Time from randomization to disease progression or death in patients who achieve CR/CRh

    Time frame: approx. 36 months

  3. Post baseline transfusion independence rate

    Transfusion independence is defined as a period of 56 days with no transfusion between the first dose of study drug and the last dose of study drug + 30 days. The rate of conversion of red blood cells (RBC) and platelets is defined as percentage of participants being post-baseline transfusion independent from baseline transfusion dependent

    Time frame: approx. 36 months

  4. Progression-free survival

    Time from randomization until first evidence of disease progression or death

    Time frame: approx. 36 months

  5. Relapse-free survival

    Number of participants alive without relapse

    Time frame: approx. 36 months

  6. Overall survival

    Time from randomization to death

    Time frame: approx. 36 months

  7. Percentage of patients bridged to hematopoietic stem cell transplantation

    Number of hematopoietic stem cell transplantations following response

    Time frame: approx. 36 months

  8. (Parts 2 & 3) Impact of treatment on HM-PRO (hematologic malignancy specific patient reported outcome measure)

    The HM-PRO consists of two scales, Part A (Impact) that measures treatment impact on patient's health-related quality of life using a three-point Likert scale (Not at all, A little, A lot) and Part B (Signs and Symptoms) that captures the severity of disease or treatment related signs and symptoms on a three-point Likert scale (Not at all, Mild, Severe).

    Time frame: approx. 36 months

07

Study locations

32 of 37 sites recruiting
  • Centre Hospitalier Universitaire Grenoble Alpes
    Grenoble, 38043, France
    Recruiting
    • Claude-Eric Bulabois, Dr · Contact
    • Claude-Eric Bulabois, Dr · Principal investigator
  • Centre Hospitalier Le Mans
    Le Mans, 72037, France
    Recruiting
    • Kamel Laribi, Dr · Contact
    • Kamel Laribi, Dr · Principal investigator
  • Centre Hospitalier Universitaire De Lille
    Lille, 59000, France
    Recruiting
    • Laure Goursaud, Dr · Contact
    • Laure Goursaud, Dr · Principal investigator
  • Institut Paoli-Calmettes
    Marseille, 13009, France
    Recruiting
    • Sylvian Garciaz, Dr · Contact
    • Sylvian Garciaz, Dr · Principal investigator
  • Centre Hospitalier Universitaire De Nice
    Nice, 06200, France
    Recruiting
    • Thomas Cluzeau, Dr · Contact
    • Thomas Cluzeau, Dr · Principal investigator
  • Centre Hospitalier Universitaire De Nimes
    Nîmes, 30900, France
    Recruiting
    • Stefan Wickenhauser, Dr · Contact
    • Stefan Wickenhauser, Dr · Principal investigator
  • Assistance Publique Hopitaux De Paris
    Paris, 75010, France
    Recruiting
    • Pierre Fenaux, Dr · Contact
    • Pierre Fenaux, Dr · Principal investigator
  • Centre Henri Becquerel
    Rouen, 76000, France
    Recruiting
    • Emilie Lemasle-Hue, Dr · Contact
    • Emilie Lemasle-Hue, Dr · Principal investigator
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
    Meldola, Forlì-Cesena 47014, Italy
    Recruiting
    • Maria Giannini, Dr · Contactinfo@irst.emr.it · +39 0543 739100
    • Maria Giannini, Dr · Principal investigator
  • Azienda Ospedaliero Universitaria Delle Marche
    Ancona, 60126, Italy
    Recruiting
    • Debora Capelli, Dr · Contact
    • Debora Capelli, Dr · Principal investigator
  • Univerisity of Bologna Policlinico Sant'Orsola
    Bologna, 40138, Italy
    Recruiting
    • Cristina Papayannidis, Prof. · Contact
    • Cristina Papayannidis, Prof. · Principal investigator
  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
    Brescia, 25123, Italy
    Recruiting
    • Erika Borlenghi, Dr · Contact
    • Erika Borlenghi, Dr · Principal investigator
  • Ospedale Vito Fazzi Lecce
    Lecce, 73100, Italy
    Recruiting
    • Nicola Di Renzo, Dr · Contact
    • Nicola Di Renzo, Dr · Principal investigator
  • AUSL Romagna - Ospedale S.M. Delle Croci
    Ravenna, Italy
    Recruiting
    • Giovanni Marconi, Prof. · Principal investigator
  • Azienda Ospedaliera Policlinico Universitario Tor Vergata
    Roma, 00133, Italy
    Recruiting
    • Adriano Venditti, Prof. · Contact
    • Adriano Venditti, Prof. · Principal investigator
  • Istituto Clinico Humanitas
    Rozzano, Italy
    Recruiting
    • Matteo Della Porta, Prof. · Principal investigator
  • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
    Turin, 10126, Italy
    Recruiting
    • Ernesta Audisio, Dr · Contact
    • Ernesta Audisio, Dr · Principal investigator
  • MTZ Clinical Research
    Warsaw, Mazowieckie Województwo 02-172, Poland
    Recruiting
    • Krzysztof Mądry · Contactinfo@pratia.com · +48 22 572 59 59
    • Krzysztof Mądry · Principal investigator
  • Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
    Biała Podlaska, 21-500, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
    Recruiting
    • Witold Prejzner, Dr · Contact
    • Witold Prejzner, Dr · Principal investigator
  • PRATIA Onkologia Katowice
    Katowice, Poland
    Recruiting
    • Sebastian Grosicki, Prof. · Principal investigator
  • Wojewodzki Szpital Zespolony Im.L.Rydygiera w Toruniu
    Torun, 87-100, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Instytut Hematologii i Transfuzjologii
    Warsaw, 02-776, Poland
    Recruiting
    • Ewa Lech-Marańda, Prof. · Contact
    • Ewa Lech-Marańda, Prof. · Principal investigator
  • Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
    Warsaw, 04-141, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego
    Wałbrzych, 58-309, Poland
    Recruiting
    • Aleksandra Butrym, Prof. · Contact
    • Aleksandra Butrym, Prof. · Principal investigator
  • Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii
    Wroclaw, 53-439, Poland
    Recruiting
    • Jarosław Dybko, Dr · Contact
    • Jarosław Dybko, Dr · Principal investigator
  • Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o.
    Zielona Góra, 65-046, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital Del Mar
    Barcelona, 08003, Spain
    Recruiting
    • Sara Garcia Avila, Dr · Contact
    • Sara Garcia Avila, Dr · Principal investigator
  • Hospital De La Santa Creu I Sant Pau
    Barcelona, 08041, Spain
    Recruiting
    • Guadalupe Oñate, Dr · Contact
    • Guadalupe Oñate, Dr · Principal investigator
  • Institut Catala D'oncologia
    Barcelona, 08908, Spain
    Not yet recruiting
    • Montserrat Arnan Sangerman, Dr · Contact
    • Montserrat Arnan Sangerman, Dr · Principal investigator
  • Hospital San Pedro De Alcantara
    Cáceres, 10002, Spain
    Recruiting
    • Juan Miguel Bergua Burgués, Dr · Contact
    • Juan Miguel Bergua Burgués, Dr · Principal investigator
  • MD Anderson Cancer Center
    Madrid, 28033, Spain
    Recruiting
    • Adolfo De La Fuente, Dr · Contact
    • Adolfo De La Fuente, Dr · Principal investigator
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    Recruiting
    • Irene Sanchez Vandillo, Dr · Contact
    • Irene Sanchez Vandillo, Dr · Principal investigator
  • Hospital Universitario Regional De Malaga
    Málaga, 29010, Spain
    Recruiting
    • Alejandro Luis Contento Gonzalo, Dr · Contact
    • Alejandro Luis Contento Gonzalo, Dr · Principal investigator
  • Clinica Universidad De Navarra
    Pamplona, 31008, Spain
    Recruiting
    • Ana Alfonso Pierola, Dr · Contact
    • Ana Alfonso Pierola, Dr · Principal investigator
  • University Hospital Virgen Del Rocio S.L.
    Seville, 41013, Spain
    Recruiting
    • Jose Antonio Perez Simón, Dr · Contact
    • Jose Antonio Perez Simón, Dr · Principal investigator
  • Hospital Universitario Y Politecnico La Fe
    Valencia, 46026, Spain
    Recruiting
    • Pau Montesinos Fernandez, Dr · Contact
    • Pau Montesinos Fernandez, Dr · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Aug 2027, 43 months after the start.

Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's planned 43 months is above that.

Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 5, 2024
StartActual
Jan 5, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06191263
Lead sponsor
Ryvu Therapeutics SA
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Jan 5, 2024
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

Head of Clinical Operations
Contact
clinicaltrials@ryvu.com
+48-12 -314-02-00

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SEL-120 · Romaciclib · Silevertinib

Start the discussion